Zhongshan Baiji Changsheng Pharmaceutical Co., Ltd.

Primary objectives: 1) To evaluate the safety and tolerability of SS-001 in patients with B-cell lymphoma. 2) To evaluate the maximum tolerated dose (MTD) and recommended dose (RP2D) of SS-001 for Phase II clinical trials. Secondary objectives: 1) To evaluate the human pharmacokinetic (PK) characteristics of single and multiple oral SS-001 in patients with B-cell lymphoma. 2) To evaluate the BTK target occupancy of SS-001 in peripheral blood mononuclear cells (PBMCs). 3) To preliminarily evaluate the efficacy of SS-001 in patients with B-cell lymphoma.